Christopher Sweeney, MBBS (@chrissweens1) 's Twitter Profile
Christopher Sweeney, MBBS

@chrissweens1

Cancer Researcher & Oncologist Prior @DanaFarber, Prof of Med @Harvardmed. Member @Uromigos. Dec 2022 Director @SAiGENCI and Prof at Uni of Adelaide. Views mine

ID: 3279005954

calendar_today14-07-2015 00:15:25

982 Tweet

4,4K Followers

298 Following

Praful Ravi (@prafulravi1) 's Twitter Profile Photo

It is worth noting that the effect we saw in RTOG-9202 is very similar to what was shown with use of Artera classifier in the same trial at ASCO 2023):

It is worth noting that the effect we saw in RTOG-9202 is very similar to what was shown with use of Artera classifier in the same trial at ASCO 2023):
South Australian immunoGENomics Cancer Institute (@saigenci) 's Twitter Profile Photo

Great to welcome South Australian immunoGENomics Cancer Institute's 2024-25 Summer Research Students at morning tea today. These undergraduate students are working with our researchers gaining valuable research experience and an insight into a career in science. Uni of Adelaide Adelaide Centre for Epigenetics 🧪🔬

Great to welcome <a href="/SAiGENCI/">South Australian immunoGENomics Cancer Institute</a>'s 2024-25 Summer Research Students at morning tea today. These undergraduate students are working with our researchers gaining valuable research experience and an insight into a career in science. <a href="/UniofAdelaide/">Uni of Adelaide</a> <a href="/ACEpigenetics/">Adelaide Centre for Epigenetics</a> 🧪🔬
Journal of Clinical Investigation (@jclinicalinvest) 's Twitter Profile Photo

The mechanism underlying the progression of castration-resistant prostate cancer! This month’s cover features work by Katherine Morel Beatriz Christopher Sweeney, MBBS ExpressionEngine & team showing Tristetraprolin regulates phenotypic plasticity of prostate cancer: jci.org/articles/view/…

The mechanism underlying the progression of castration-resistant prostate cancer!

This month’s cover features work by <a href="/kat_morel/">Katherine Morel</a> <a href="/BeatrizGerFalc/">Beatriz</a> <a href="/ChrisSweens1/">Christopher Sweeney, MBBS</a> <a href="/EllisLab/">ExpressionEngine</a> &amp; team showing Tristetraprolin regulates phenotypic plasticity of prostate cancer: jci.org/articles/view/…
EllisLab_ (@ellislab_) 's Twitter Profile Photo

Latest journey in #prostatecancer cell plasticity. Team effort Christopher Sweeney, MBBS Katherine Morel Beatriz Work stems from previous Christopher Sweeney, MBBS investigations in NFkB regulation by tristetraprolin (TTP; gene ZFP36), and generation of the NFkBi dimethylaminoparthenolide (DMAPT)

silke gillessen (@silke_gillessen) 's Twitter Profile Photo

We will have the efficacy data hopefully for ASCO 2026, it is a non-inferiority trial. The lower rates of hypocalcaemia for the 3-monthly regimen have been presented earlier.

Oncology Brothers (@oncbrothers) 's Twitter Profile Photo

Pluvicto now w/ expanded FDA Oncology approval based off #PSMAfore: progressive mCRPC Pluvicto Vs ARPI - rPFS 9.3 Vs 5.6mos (HR: 0.41) - ARPI ⛔️ ideal on progression after upfront ARPI. Cost & Access to keep in mind. - Summary Christopher Sweeney, MBBS from ESMO - Eur. Oncology #OncTwitter #gusm

Pluvicto now w/ expanded <a href="/FDAOncology/">FDA Oncology</a> approval based off #PSMAfore: progressive mCRPC Pluvicto Vs ARPI 

- rPFS 9.3 Vs 5.6mos (HR: 0.41)
- ARPI ⛔️ ideal on progression after upfront ARPI. Cost &amp; Access to keep in mind. 
- Summary <a href="/ChrisSweens1/">Christopher Sweeney, MBBS</a> from <a href="/myESMO/">ESMO - Eur. Oncology</a> 

#OncTwitter #gusm
South Australian immunoGENomics Cancer Institute (@saigenci) 's Twitter Profile Photo

Great to see a full-house for South Australian immunoGENomics Cancer Institute's third Annual Public Lecture on Tuesday night featuring Jenkins Lab and Dr. Mara Zeissig speaking on the topic of "Fighting cancer from within: your immune system may hold the key" youtube.com/watch?v=z2KcRI… Uni of Adelaide

Great to see a full-house for <a href="/SAiGENCI/">South Australian immunoGENomics Cancer Institute</a>'s third Annual Public Lecture on Tuesday night featuring <a href="/Lab_Jenkins/">Jenkins Lab</a> and <a href="/marazeissig/">Dr. Mara Zeissig</a>  speaking on the topic of "Fighting cancer from within:  your immune system may hold the key" youtube.com/watch?v=z2KcRI… <a href="/UniofAdelaide/">Uni of Adelaide</a>
Uromigos (@uromigos) 's Twitter Profile Photo

🚨 New episode alert! silke gillessen and Christopher Sweeney, MBBS join us to discuss our latest 'Uromigos Score' in which experts score the value of treatments for advanced prostate cancer. Expect some interesting themes and insights. 🎙️ GU Oncology Now: buff.ly/GzQAw1J 🍎

🚨 New episode alert! <a href="/Silke_Gillessen/">silke gillessen</a> and <a href="/ChrisSweens1/">Christopher Sweeney, MBBS</a> join us to discuss our latest 'Uromigos Score' in which experts score the value of treatments for advanced prostate cancer. Expect some interesting themes and insights. 

🎙️ GU Oncology Now: buff.ly/GzQAw1J
 🍎
Ian Davis (@prof_iand) 's Twitter Profile Photo

#BCGMM presented by Dickon Hayne at #ASCO25. Simple question, hard trial, needed a cooperative group like ANZUP NHMRC CTC. Discussant Dr. John Sfakianos v enthusiastic, one of the most impactful #NMIBC trials he has seen, will change his practice. #BladderCancer #blcsm

Tom Powles (@tompowles1) 's Twitter Profile Photo

Uromigos unsung prostate cancer hero #ASC025 @dolmos77 - David Olmos - 50% 8 year OS for M1 1st line disease - but subgroups (PSMA+ve and BRCA) still have less good outcomes. Opportunities for further therapy her e with PARPi and LuPSMA (+ve PSMA addition and amplitude studies)

Ian Davis (@prof_iand) 's Twitter Profile Photo

#ENZAMET ANZUP NHMRC CTC #ASCO25 ✅ 50% survival at 8yr vs 40% - sustained, all subgroups ✅ non-#ProstateCancer deaths same in both arms: removes doubts of long term safety and benefit re competing causes of death ✅ undetectable PSA is good; more likely with enza

Advanced Prostate Cancer Consensus Conference (@apccc_lugano) 's Twitter Profile Photo

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol sciencedirect.com/science/articl… In the STAMPEDE phase 3 trial, researchers evaluated whether adding metformin to standard of care

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol

sciencedirect.com/science/articl…

In the STAMPEDE phase 3 trial, researchers evaluated whether adding metformin to standard of care
The Lancet Oncology (@thelancetoncol) 's Twitter Profile Photo

Online: Metformin for patients with metastatic #prostatecancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol silke gillessen, Nick James also on @Prof-Nick-James.bsky.social, Ashwin Sachdeva, and colleagues thelancet.com/journals/lanon…

Online: Metformin for patients with metastatic #prostatecancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol

<a href="/Silke_Gillessen/">silke gillessen</a>, <a href="/Prof_Nick_James/">Nick James also on @Prof-Nick-James.bsky.social</a>,  <a href="/AshwinUrol/">Ashwin Sachdeva</a>, and colleagues

thelancet.com/journals/lanon…